Anika Therapeutics | ANIK - Cash And Equivalent


Anika Therapeutics reported $41.02M in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
Abbott USD 6.8B 1.72B Mar/2026
Agenus USD 35M 32M Mar/2026
Agios Pharmaceuticals USD 113.6M 24.47M Mar/2026
Anika Therapeutics USD 41.02M 16.46M Mar/2026
Arrowhead Research USD 201.64M 112.94M Dec/2025
Enanta Pharmaceuticals USD 37.44M 5.14M Dec/2025
Halozyme Therapeutics USD 309.75M 175.93M Mar/2026
Heron Therapeutics USD 26.12M 2.53M Mar/2026
Insmed USD 582.19M 71.74M Mar/2026
Integra LifeSciences USD 236.81M 1.76M Mar/2026
Intrexon USD 9.34M 1.77M Jun/2024
J&J USD 21.69B 1.98B Mar/2026
Karyopharm Therapeutics USD 60.54M 22.87M Dec/2025
Ligand Pharmaceuticals USD 115.08M 59.85M Mar/2026
MacroGenics USD 66.52M 9.3M Mar/2026
Merit Medical Systems USD 488.08M 41.68M Mar/2026
Rigel Pharmaceuticals USD 48.53M 4.87M Sep/2025
Sangamo BioSciences USD 38.34M 13.16M Jun/2025
Sanofi EUR 7.66B 1.25B Dec/2025
Stryker USD 2.88B 1.13B Mar/2026
Veracyte USD 263.14M 99.44M Mar/2026
Xencor USD 14.17M 39.9M Mar/2026
Zimmer Biomet Holdings USD 424.2M 167.7M Mar/2026